Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hypertension affects approximately one-quarter of the adult population, yet only 20–25% of patients achieve target blood pressure (BP) control. This unsatisfactory rate is partly due to treatment-resistant hypertension, which often requires combination therapy with multiple antihypertensive drugs. However, adverse effects remain a major concern, especially for elderly patients. Therefore, antihypertensive strategies utilizing naturally derived compounds with superior biocompatibility and minimal side effects have attracted growing attention. We investigated the antihypertensive effects of extract X, which is derived from natural fibers, using spontaneously hypertensive rats (SHR). SHR is a well-established model of human essential hypertension characterized by sympathetic overactivity and enhanced renin–angiotensin system (RAS) activity. This study aimed to determine whether extract X suppresses BP elevation in SHR and to explore its underlying mechanisms.
Eight-week-old male spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats were randomly assigned to vehicle- or X-treated groups and maintained until 12 weeks of age. Systolic blood pressure (BP) was measured blindly by the tail-cuff method at 8 and 12 weeks. Upon sacrifice, blood, urine, and major organs (kidneys, hearts, brains, and skin) were collected. Urinary catecholamines, as well as plasma and tissue angiotensin II (Ang II) and renin–angiotensin system (RAS)-related components, were quantified.
At 12 weeks, SHR-vehicle had a markedly higher systolic BP than WKY-vehicle (175.3 ± 4.1 vs. 116.2 ± 2.1 mmHg, p < 0.0001). Notably, X treatment significantly reduced systolic BP in SHR (162.5 ± 1.4 vs. 175.3 ± 4.1 mmHg, p < 0.05). SHR exhibited elevated plasma and tissue Ang II levels compared with WKY. However, X did not significantly alter these RAS parameters. In contrast, urinary adrenaline levels were higher in SHR than in WKY, and X tended to attenuate this elevation. These findings suggest that X primarily exerts its antihypertensive effect through modulation of sympathetic nerve activity.
The natural fiber-derived extract X significantly lowered systolic BP in SHR, indicating its potential as a novel, biocompatible antihypertensive agent. This effect is likely mediated by the attenuation of sympathetic nerve activity; however, further studies are needed to elucidate the detailed pathways. These findings support the therapeutic potential of naturally derived bioactive compounds for safely managing hypertension.
